Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Net Margin (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Net Margin data on record, last reported at 972.95% in Q3 2025.

  • For Q3 2025, Net Margin fell 46930.0% year-over-year to 972.95%; the TTM value through Sep 2025 reached 963.38%, up 83707.0%, while the annual FY2024 figure was 1288.25%, 21353.0% up from the prior year.
  • Net Margin reached 972.95% in Q3 2025 per TNXP's latest filing, up from 1415.02% in the prior quarter.
  • Across five years, Net Margin topped out at 503.65% in Q3 2024 and bottomed at 3567.75% in Q2 2024.
  • Average Net Margin over 3 years is 1123.53%, with a median of 800.11% recorded in 2023.
  • Peak YoY movement for Net Margin: tumbled -276764bps in 2024, then surged 215274bps in 2025.
  • A 3-year view of Net Margin shows it stood at 701.3% in 2023, then fell by -22bps to 856.24% in 2024, then fell by -14bps to 972.95% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 972.95% in Q3 2025, 1415.02% in Q2 2025, and 692.84% in Q1 2025.